Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 1

Interventions

pembrolizumab 35 Carboplatin 24 Specimen Handling 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 fludarabine 15 Nivolumab 14 Dexamethasone 14 Bevacizumab 14 Gemcitabine 12 Biopsy 12 atezolizumab 11 Temozolomide 11 Paclitaxel 10 venetoclax 9 Pemetrexed 9 Ipilimumab 9 Docetaxel 9 Cisplatin 9 Rituximab 8 Lenalidomide 8 blinatumomab 7 Prednisone 7 Oxaliplatin 7 Fluorouracil 7 Capecitabine 7 olaparib 6 lenvatinib 6 Vincristine 6 Radiotherapy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Antiemetics × 30 days × Clear all

NCT06242691 2026-06-05

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed

13 enrolled 21 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡